공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 부인과계 질환 치료제 시장 조사와 분석

Global Women Health Therapeutics Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2019년 12월 상품 코드 486703
페이지 정보 영문
가격
US $ 3,600 ₩ 3,983,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,311,000 Printable PDF (Enterprise License)


세계의 부인과계 질환 치료제 시장 조사와 분석 Global Women Health Therapeutics Market 2019-2025
발행일 : 2019년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 부인과계 질환 치료제(Women Health Therapeutics) 시장에 대해 분석했으며, 질환·기술 개요와 시장의 기본 구조, 외부로부터의 거시적·미시적 영향, 주요 성장 촉진·억제요인, 질환별·지역별 시장 동향 전망(과거 2년간, 향후 6년간), 최신 시장 경쟁 상황, 주요 기업 개요와 최신 동향 등의 정보를 전해드립니다.

제1장 분석 개요

제2장 시장 개요와 통찰

  • 정의
  • 애널리스트의 견해와 현재 시장 동향
    • 분석 포인트
    • 제안
    • 결론
  • 세계 각국의 규제
  • 특허 분석

제3장 시장 결정요인

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회

제4장 시장 세분화

  • 부인과계 질환 치료제 시장 : 질환·증상별
    • 폐경
    • 자궁내막증
    • 폐경후 골다공증
    • 유방암
    • 다낭성난소증후군(PCOS)
    • 불임
    • 부인과계 암
    • 기타

제5장 경쟁 구도

  • 시장 점유율 분석
  • 주요 기업 분석

제6장 지역 분석

  • 북미(미국, 캐나다 등)
  • 유럽(영국, 프랑스, 독일, 이탈리아, 스페인 등)
  • 아시아태평양 지역(인도, 중국, 일본 등)
  • 기타 국가(RoW)

제7장 기업 개요

KSM 17.04.28

List of Tables

1. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

2. GLOBAL INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

3. GLOBAL PREGANANCY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

4. GLOBAL ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

5. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

6. GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

7. GLOBAL AMBULATORY CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)

8. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)

9. NORTH AMERICAN WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

10. NORTH AMERICAN WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

11. NORTH AMERICAN WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

12. EUROPEAN WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

13. EUROPEAN WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

14. EUROPEAN WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

15. ASIA-PACIFIC WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)

16. ASIA-PACIFIC WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

17. ASIA-PACIFIC WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

18. REST OF THE WORLD WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

19. REST OF THE WORLD WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

List of Figures

1. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET SHARE BY TYPE, 2018 VS 2025 (%)

2. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET SHARE BY END-USER, 2018 VS 2025 (%)

3. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)

4. THE US WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

5. CANADA WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

6. UK WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

7. FRANCE WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

8. GERMANY WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

9. ITALY WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

10. SPAIN WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

11. ROE WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

12. INDIA WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

13. CHINA WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

14. JAPAN WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

15. REST OF ASIA-PACIFIC WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

16. REST OF THE WORLD WOMEN HEALTH THERAPEUTIC MARKET SIZE, 2018-2025 ($ MILLION)

Global Women Health Therapeutics Market Size, Share & Trends Analysis Report by Type (Infection, Pregnancy, and Oncology) and by End-User (Hospitals and Clinics and Ambulatory Centers) and Forecast 2019-2025

Global women health therapeutics market is anticipated to exhibit a significant growth at a CAGR 4.4% during the forecast period. In the healthcare industry, women health therapeutics market is a constantly growing segment as every woman has to deal with some kind of gynecological disorder at some point in their lifetime. While most of the gynecological diseases can be cured with proper treatment; however, in certain cases, they can prove fatal unless diagnosed at the right time. In present times, women health therapeutics market has a notable pipeline of promising molecules at several stages of clinical development. Some of such molecules are AZD4901, romosozumab (AMG785), abaloparatide, elagolix, ASP1707, vaginorm, and teriparatide. However, the patent expiry of drugs is expected to pose challenges in the growth of the global women health therapeutics market. Furthermore, supportive government initiatives coupled with improving healthcare infrastructure in emerging economies are projected to create significant growth opportunities for the global market.

The global women health therapeutics market is segmented on the basis of type and end-user. Based on type, the market is segmented into an infection, pregnancy, and oncology. Based on end-user, the market is bifurcated into hospitals and clinics and ambulatory centers. Infection is accounted for the substantial market share and is expected to maintain its presence in the market during the forecast period. This is due to the high incidence of infectious diseases, increasing drug approvals, and the availability of diagnostics tests and treatments.

Global women health therapeutics market can be segmented geographically into North America, Europe, Asia-Pacific, and Rest of the World. Amongst them, North America and Europe held a significant share in the global market, owing to the growing focus towards women health and increasing elderly population. The high prevalence of chronic disorders such as breast cancer in the US further propels the growth of the women health therapeutics market in North America. The rapidly emerging economies of Asia-Pacific are projected to witness the considerable growth rate in the global market during the forecast period. The growth is backed by the growing awareness about the diversified treatment options for women health issues coupled with the rising prevalence of urological disorders within the region.

The key players of women health therapeutics market include Novartis AG, Abbott Laboratories, Inc., Pfizer Inc., Eli Lilly and Co., Bayer AG, Merck KGaA, Novo Nordisk A/S, and F. Hoffmann-La Roche Ltd. Product launch, merger and acquisition, and partnerships are some of the key strategies adopted by the market players and sustain and capture the major market share in the women health therapeutics market.

Research Methodology

The market study of the global women health therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for pharmaceutical companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Women Health Therapeutics Market Research and Analysis by Type

2. Global Women Health Therapeutics Market Research and Analysis by End-User

The Report Covers

  • Comprehensive research methodology of the global women health therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global women health therapeutics market.
  • Insights about market determinants which are stimulating the global women health therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Abbott Laboratories, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. F. Hoffmann-La Roche LTD.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Novartis AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Bayer AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Eli Lilly and Co.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

4.1 Motivators

4.2 Restraints

  • 4.1. Opportunities

5. Market Segmentation

  • 5.1. Global Women Health Therapeutics Market by Type
    • 5.1.1. Infection
    • 5.1.2. Pregnancy
    • 5.1.3. Oncology
      • 5.1.3.1. Cervical Cancer
      • 5.1.3.2. Uterine Cancer
      • 5.1.3.3. Ovarian cancer
      • 5.1.3.4. Vaginal & Vulvar Cancer
  • 5.2. Global Women Health Therapeutics Market by End-User
    • 5.2.1. Hospital and Clinics
    • 5.2.2. Ambulatory Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories, Inc.
  • 7.2. Allergan PLC
  • 7.3. Amgen Inc.
  • 7.4. Astellas Pharma Inc.
  • 7.5. Bayer AG
  • 7.6. Eli Lilly and Co.
  • 7.7. F. Hoffmann-La Roche Ltd.
  • 7.8. ICON PLC
  • 7.9. Merck KGaA
  • 7.10. Mithra Pharmaceuticals S.A.
  • 7.11. Novartis AG
  • 7.12. Novo Nordisk A/S
  • 7.13. Pfizer Inc.
  • 7.14. Oasmia Pharmaceutical AB
  • 7.15. ObsEva SA
  • 7.16. Radius Health, Inc.
  • 7.17. Sanofi SA
  • 7.18. Takeda Pharmaceutical Co. Ltd.
  • 7.19. Teva Pharmaceuticals Industries Ltd.
  • 7.20. Tsumura & Co.
Back to Top
전화 문의
F A Q